Product Code: ETC070905 | Publication Date: Jun 2023 | Updated Date: Feb 2025 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The Malaysia DNA Damage Response Drugs Market is estimated to grow at a CAGR of 12.8% during the forecast period 2025-2031. The increasing occurrences of cancer cases, continuous efforts from the government for better healthcare facilities and rising investment in clinical research activities are likely to drive market growth over the forecast period
The high incidence rate of cancer in Malaysia has created an upsurge in demand for effective drugs for treating it. This is expected to be one of the major drivers responsible for fuelling market growth over the forecast period 2025-2031. According to World Health Organization (WHO), around 11,246 new cases were reported in 2018 with breast cancer being the most common type among women accounting for 29% followed by colorectal cancer that accounted 15%. Thus, growing prevalence of cancers such as lung, skin and prostate owing which necessitates use of DNA damage response drugs will further spur industry expansion over upcoming years.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Malaysia DNA Damage Response Drugs Market Overview |
3.1 Malaysia Country Macro Economic Indicators |
3.2 Malaysia DNA Damage Response Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Malaysia DNA Damage Response Drugs Market - Industry Life Cycle |
3.4 Malaysia DNA Damage Response Drugs Market - Porter's Five Forces |
3.5 Malaysia DNA Damage Response Drugs Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Malaysia DNA Damage Response Drugs Market Revenues & Volume Share, By Applications, 2021 & 2031F |
4 Malaysia DNA Damage Response Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Malaysia DNA Damage Response Drugs Market Trends |
6 Malaysia DNA Damage Response Drugs Market, By Types |
6.1 Malaysia DNA Damage Response Drugs Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Malaysia DNA Damage Response Drugs Market Revenues & Volume, By Type, 2018 - 2031F |
6.1.3 Malaysia DNA Damage Response Drugs Market Revenues & Volume, By PARP, 2018 - 2031F |
6.1.4 Malaysia DNA Damage Response Drugs Market Revenues & Volume, By Inhibitors, 2018 - 2031F |
6.1.5 Malaysia DNA Damage Response Drugs Market Revenues & Volume, By Others, 2018 - 2031F |
6.2 Malaysia DNA Damage Response Drugs Market, By Applications |
6.2.1 Overview and Analysis |
6.2.2 Malaysia DNA Damage Response Drugs Market Revenues & Volume, By Oncology, 2018 - 2031F |
6.2.3 Malaysia DNA Damage Response Drugs Market Revenues & Volume, By Stroke, 2018 - 2031F |
6.2.4 Malaysia DNA Damage Response Drugs Market Revenues & Volume, By Radiotherapy, 2018 - 2031F |
7 Malaysia DNA Damage Response Drugs Market Import-Export Trade Statistics |
7.1 Malaysia DNA Damage Response Drugs Market Export to Major Countries |
7.2 Malaysia DNA Damage Response Drugs Market Imports from Major Countries |
8 Malaysia DNA Damage Response Drugs Market Key Performance Indicators |
9 Malaysia DNA Damage Response Drugs Market - Opportunity Assessment |
9.1 Malaysia DNA Damage Response Drugs Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Malaysia DNA Damage Response Drugs Market Opportunity Assessment, By Applications, 2021 & 2031F |
10 Malaysia DNA Damage Response Drugs Market - Competitive Landscape |
10.1 Malaysia DNA Damage Response Drugs Market Revenue Share, By Companies, 2024 |
10.2 Malaysia DNA Damage Response Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |